Literature DB >> 15946311

Recurrent V75M mutation within the Wiskott-Aldrich syndrome protein: description of a homozygous female patient.

Alexis Proust1, Benoît Guillet, Isabelle Pellier, Petronela Rachieru, Cyrille Hoarau, Ségolène Claeyssens, Claude Léonard, Sabine Charrier, William Vainchenker, Gil Tchernia, Jean Delaunay.   

Abstract

The Wiskott-Aldrich syndrome is a rare genetic disorder due to mutations in the WAS gene situated on chromosome X. It is comprised of microthrombocytopenia, eczema and immunodeficiency. However, the phenotypical presentation may vary as to the number and intensity of its manifestations. A milder form of Wiskott-Aldrich syndrome is known as the X-linked thrombocytopenia. We independently found eight individual or familial cases with the V75M substitution (9.76%). This high incidence was partly accounted for by the fact that three cases turned out to be related. The V75M mutation is recurrent, however, due to a CpG island. A genuine homozygous female patient was found. She showed microthrombocytopenia and infections to the same degree as her hemizygous father and brother. The WAS protein was decreased in a comparable fashion in the hemizygotes and the homozygote as well. Its amount was about 10% and 15% of normal in platelets and mononucleated white cells, respectively. In all patients was the picture consistent with XLT. (c) Blackwell Munksgaard 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946311     DOI: 10.1111/j.1600-0609.2005.00415.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  1 in total

1.  A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP.

Authors:  Gaetana Lanzi; Daniele Moratto; Donatella Vairo; Stefania Masneri; Ottavia Delmonte; Tiziana Paganini; Silvia Parolini; Giovanna Tabellini; Cinzia Mazza; Gianfranco Savoldi; Davide Montin; Silvana Martino; Pierangelo Tovo; Itai M Pessach; Michel J Massaad; Narayanaswamy Ramesh; Fulvio Porta; Alessandro Plebani; Luigi D Notarangelo; Raif S Geha; Silvia Giliani
Journal:  J Exp Med       Date:  2012-01-09       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.